PT968722E - Vacina viva melhorada contra brsv. - Google Patents
Vacina viva melhorada contra brsv. Download PDFInfo
- Publication number
- PT968722E PT968722E PT99115633T PT99115633T PT968722E PT 968722 E PT968722 E PT 968722E PT 99115633 T PT99115633 T PT 99115633T PT 99115633 T PT99115633 T PT 99115633T PT 968722 E PT968722 E PT 968722E
- Authority
- PT
- Portugal
- Prior art keywords
- virus
- adjuvants
- vet
- adjuvant
- immunity
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract 5
- 239000002671 adjuvant Substances 0.000 claims abstract 13
- 241000711895 Bovine orthopneumovirus Species 0.000 claims abstract 11
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims abstract 6
- 230000036039 immunity Effects 0.000 claims abstract 5
- 208000015181 infectious disease Diseases 0.000 claims abstract 4
- 239000004094 surface-active agent Substances 0.000 claims abstract 4
- 239000000203 mixture Substances 0.000 claims abstract 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract 3
- -1 polyoxypropylene Polymers 0.000 claims abstract 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims abstract 2
- 230000024932 T cell mediated immunity Effects 0.000 claims abstract 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims abstract 2
- 229920001400 block copolymer Polymers 0.000 claims abstract 2
- 230000028993 immune response Effects 0.000 claims abstract 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims abstract 2
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract 2
- 229940032094 squalane Drugs 0.000 claims abstract 2
- 229940031439 squalene Drugs 0.000 claims abstract 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims abstract 2
- 241000700605 Viruses Species 0.000 claims 5
- 241000283690 Bos taurus Species 0.000 claims 3
- 241000186216 Corynebacterium Species 0.000 claims 2
- 229920002307 Dextran Polymers 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 2
- 229960002086 dextran Drugs 0.000 claims 2
- 229940047124 interferons Drugs 0.000 claims 2
- 230000008774 maternal effect Effects 0.000 claims 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 2
- 229930182490 saponin Natural products 0.000 claims 2
- 150000007949 saponins Chemical class 0.000 claims 2
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims 1
- 241000701083 Bovine alphaherpesvirus 1 Species 0.000 claims 1
- 102000009016 Cholera Toxin Human genes 0.000 claims 1
- 108010049048 Cholera Toxin Proteins 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 108010015899 Glycopeptides Proteins 0.000 claims 1
- 102000002068 Glycopeptides Human genes 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 102000013967 Monokines Human genes 0.000 claims 1
- 108010050619 Monokines Proteins 0.000 claims 1
- 241000186366 Mycobacterium bovis Species 0.000 claims 1
- 241000702259 Orbivirus Species 0.000 claims 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 1
- 241000186429 Propionibacterium Species 0.000 claims 1
- 208000035415 Reinfection Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 1
- 241000700647 Variola virus Species 0.000 claims 1
- 229920006243 acrylic copolymer Polymers 0.000 claims 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims 1
- WXNRAKRZUCLRBP-UHFFFAOYSA-N avridine Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 claims 1
- 229950010555 avridine Drugs 0.000 claims 1
- 229960000074 biopharmaceutical Drugs 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 210000002421 cell wall Anatomy 0.000 claims 1
- 239000003599 detergent Substances 0.000 claims 1
- 229960000633 dextran sulfate Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 230000002134 immunopathologic effect Effects 0.000 claims 1
- 229940117681 interleukin-12 Drugs 0.000 claims 1
- 229940047122 interleukins Drugs 0.000 claims 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 230000007246 mechanism Effects 0.000 claims 1
- 239000002480 mineral oil Substances 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 235000019198 oils Nutrition 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229940055019 propionibacterium acne Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 102000003390 tumor necrosis factor Human genes 0.000 claims 1
- 208000007089 vaccinia Diseases 0.000 claims 1
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 1
- 239000008158 vegetable oil Substances 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 3
- 229920001451 polypropylene glycol Polymers 0.000 abstract 2
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 150000002430 hydrocarbons Chemical class 0.000 abstract 1
- 230000003248 secreting effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (5)
- ΡΕ968722 1 REIVINDICAÇÕES 1. Utilização de um Vírus Sincitial Respiratório de Bovinos modificado vivo e de um ou mais adjuvantes em combinação com um ou mais estabilizadores, veículos e adjuvantes aceitáveis do ponto de vista farmacêutico, seleccionados de entre os adjuvantes que proporcionem uma resposta imunológica multifacetada contra o BRSV modificado, sendo os adjuvantes referidos seleccionados de entre aqueles que proporcionem imunidade mediada por células e imunidade local (IgA segregado) e que para além disso sejam elementos do conjunto constituído por: esqualano e o esqualeno (ou outros óleos de origem animal); copolímeros em blocos, de preferência Pluronic® (L121); Saponina; detergentes ou tensioactivos não iónicos, de preferência mono-oleato de polioxietileno(20)-sorbitano Tween®- -80; Quil® A, óleos minerais, de preferência Drakeol® ou Marcol®, óleos vegetais; adjuvantes provenientes de Corynebacterium como por exemplo de Corynebacterium parvum; adjuvantes provenientes de Propionibacterium, de preferência de Propionibacterium acne; Mycobacterium bovis (Bacíllus Calmette e Guerinn, ou BCG); interleuquinas seleccionadas de entre a interleuqina 2 e a interleuquina-12; monoquinas, de preferência a interleuquina 1; factor de necrose tumoral; interferões de preferência interferões gama; combinações de saponina com hidróxido de alumínio ou 2 ΡΕ968722 de Quil® com hidróxido de alumínio; lipossomas; adjuvante iscom; extracto de paredes celulares de micobactérias; glicopéptidos sintéticos, de preferência dipéptidos muramílicos ou outros derivados; Avridina; Lípido A; sulfato de dextrano; DEAE-Dextrano ou DEAE-Dextrano com fosfato de alumínio; carboxipolimetilenos, de preferência o Carbopol®; EMA; emulsões de copolímeros acrílicos, de preferência Neocryl® A640; proteínas de vaccinia ou de vírus de varíola; adjuvantes que sejam partículas subvirais. de preferência o orbivirus; toxina da cólera; brometo de dimetildiocledecilmónio; ou misturas destes, na preparação de uma vacina de Vírus Sincitial Respiratório de Bovinos de dose única, de tal forma que a vacina origine uma imunidade positiva contra a infecção por BRSV após uma única administração.
- 2. A utilização de acordo com a reivindicação 1, em que o adjuvante inclua também um tensioactivo.
- 3. A utilização de acordo com a reivindicação 2, em que o adjuvante também inclua um tensioactivo presente numa concentração final de cerca de 0,0015 a 0,20 % (em volume).
- 4. A utilização de acordo com a reivindicação 2 ou a 3, em que o tensioactivo seja mono-oleato de poli-oxietileno-sorbitano. 3 ΡΕ968722
- 5. A utilização de acordo com qualquer uma das reivindicações 1 a 4, em que a vacina também inclua Virus de Rino-traqueite de Bovinos (BHV-IV), Virus de Diarreia de Bovinos (BVDV), e Virus de Parainfluenza 3 (PI-3V). Lisboa, 27 de Agosto de 2007 ι ΡΕ968722 BIBLIOGRAFIA CITADA NA DESCRIÇÃO A lista da bibliografia citada pela requerente destina-se unicamente ao leitor. Ela não integra o documento de patente Europeia. Ainda que se tenha tido grande cuidado na compilação da bibliografia, não se podem excluir erros nem omissões, e o EPO rejeita qualquer responsabilidade a este respeito. Documentos de patentes citados na descrição • EP 129923 A • US 4772466 A • US 5047238 A Outra literatura citada na descrição • KIMMAN e tal. J. Clin. • Vet. Immunol. Immunopathol., 1989, Microbiol., 1987, 25, 1097- 22(2), 145-160. 1106 . • Bovine Respiratory Syncytial Vírus • STOTT et al. J. Hyg. Camb. and the effect of the amount of 1984, 93, 251-261. vírus, vírus replication, route of • THOMAS et al. Agri-Practice, administration and maternal 1986, 5. antibodies, J. Clin. Microbiol., • SYVRUD et al. Vet. Med., 1987, 25(6), 1.097-1.106 1988, 83, 429-430. • Bovine Respiratory Syncytial Virus • Veterinary Pharmaceuticals & infection, and re-infection in cal- Biologicals. 1993, 78, 484, ves with and without maternal anti 740-741, 956-960, 982-983. bodies. Vet Q., 1991, 13(1), 47-59 • Agri-Practice. Vet. Med. • BAKER, Human and Bovine Respiratory Outubro 1983, 78, 1599-1604. Syncytial Virus immunopathologic • Bovine Vet. Fórum 1, 16 de mechanisms. Semin. Immunol. 1990, Fevereiro de 1986, 2. 2(5), 369-374, • SVYRUD et al. Vet. Med., • THOMAS et al., Agri-Practice 7(5), 1988, 429-430 26-30
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24037394A | 1994-05-10 | 1994-05-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT968722E true PT968722E (pt) | 2007-09-06 |
Family
ID=22906268
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT70083787T PT1820512E (pt) | 1994-05-10 | 1995-05-08 | Vacina viva modificada melhorada contra brsv |
| PT95918442T PT759780E (pt) | 1994-05-10 | 1995-05-08 | Vacina melhorada de vsrb vivo modificado |
| PT99115633T PT968722E (pt) | 1994-05-10 | 1995-05-08 | Vacina viva melhorada contra brsv. |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT70083787T PT1820512E (pt) | 1994-05-10 | 1995-05-08 | Vacina viva modificada melhorada contra brsv |
| PT95918442T PT759780E (pt) | 1994-05-10 | 1995-05-08 | Vacina melhorada de vsrb vivo modificado |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US5733555A (pt) |
| EP (4) | EP0968722B1 (pt) |
| JP (3) | JP3993230B2 (pt) |
| KR (1) | KR100374434B1 (pt) |
| CN (1) | CN1268393C (pt) |
| AT (2) | ATE365049T1 (pt) |
| AU (1) | AU711350B2 (pt) |
| BR (1) | BR9507717A (pt) |
| CA (1) | CA2189979C (pt) |
| DE (2) | DE69518316T2 (pt) |
| DK (2) | DK0759780T3 (pt) |
| ES (3) | ES2287997T3 (pt) |
| GR (1) | GR3034402T3 (pt) |
| HK (1) | HK1024412A1 (pt) |
| MY (1) | MY111829A (pt) |
| NZ (1) | NZ285324A (pt) |
| PT (3) | PT1820512E (pt) |
| SI (2) | SI0968722T1 (pt) |
| WO (1) | WO1995030437A1 (pt) |
| ZA (1) | ZA953703B (pt) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6673335B1 (en) * | 1992-07-08 | 2004-01-06 | Nektar Therapeutics | Compositions and methods for the pulmonary delivery of aerosolized medicaments |
| US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| US6231851B1 (en) * | 1994-05-18 | 2001-05-15 | Inhale Therapeutic Systems | Methods and compositions for the dry powder formulation of interferons |
| WO1994007514A1 (en) * | 1992-09-29 | 1994-04-14 | Inhale Therapeutic Systems | Pulmonary delivery of active fragments of parathyroid hormone |
| CA2136677A1 (en) * | 1993-12-29 | 1995-06-30 | Intervet, Inc. | Method of intranasally administering to bovines a trivalent vaccine containing modified live ibrv, pl3v and brsv |
| US20030113273A1 (en) * | 1996-06-17 | 2003-06-19 | Patton John S. | Methods and compositions for pulmonary delivery of insulin |
| CZ295827B6 (cs) * | 1994-03-07 | 2005-11-16 | Nektar Therapeutics | Způsob aerosolizace dávky inzulinu, inzulinový přípravek a jeho použití |
| ZA953703B (en) * | 1994-05-10 | 1996-01-10 | American Home Prod | Modified live BRSV vaccine |
| US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
| WO1996011019A1 (en) * | 1994-10-05 | 1996-04-18 | Vanderbilt University | Interleukin-12 as an adjuvant for paramyxoviridae vaccines |
| US6359054B1 (en) * | 1994-11-18 | 2002-03-19 | Supratek Pharma Inc. | Polynucleotide compositions for intramuscular administration |
| US20030035778A1 (en) * | 1997-07-14 | 2003-02-20 | Robert Platz | Methods and compositions for the dry powder formulation of interferon |
| US6309623B1 (en) * | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US20060165606A1 (en) * | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| US6908618B2 (en) | 1997-11-10 | 2005-06-21 | University Of Maryland | Production of novel bovine respiratory syncytial viruses from cDNAs |
| FR2772047B1 (fr) | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection |
| FR2775601B1 (fr) * | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
| TW440845B (en) | 1999-08-11 | 2001-06-16 | Ibm | Method and system for programming FPGAs on PC-cards without additional hardware |
| US8404217B2 (en) * | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
| US7871598B1 (en) * | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| TWI290473B (en) | 2000-05-10 | 2007-12-01 | Alliance Pharma | Phospholipid-based powders for drug delivery |
| AU2001280934A1 (en) * | 2000-07-28 | 2002-02-13 | Alliance Pharmaceutical Corp. | Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds |
| MY129765A (en) * | 2000-12-19 | 2007-04-30 | Wyeth Corp | Improved mycoplasma hyopneumoniae bacterin vaccine |
| US7018638B2 (en) * | 2000-12-19 | 2006-03-28 | Wyeth | Mycoplasma hyopneumoniae bacterin vaccine |
| AU2002342568B2 (en) | 2001-05-10 | 2007-11-01 | Wyeth | Composition and method for increasing cell density in cell cultures infected with lentivirus |
| AU2002309109B2 (en) | 2001-07-02 | 2007-12-13 | Zoetis Services Llc | One dose vaccination with mycoplasma hyopneumoniae |
| CN1935258B (zh) | 2001-07-27 | 2013-04-03 | 惠氏公司 | 西尼罗河疫苗 |
| US20030129161A1 (en) * | 2001-09-17 | 2003-07-10 | Hsien-Jue Chu | Interleukin-12 as a veterinary vaccine adjuvant |
| ES2364636T3 (es) | 2001-12-19 | 2011-09-08 | Novartis Ag | Administración pulmonar de aminoglucósidos. |
| CA2496750C (en) * | 2002-08-26 | 2014-10-21 | Pfizer Products Inc. | Vaccine for respiratory and reproductive system infections in cattle |
| MXPA06007207A (es) * | 2003-12-23 | 2006-08-18 | Schering Corp | Metodos para la produccion de lineas de celulas a549 estables en cultivo en suspension de medio libre de suero. |
| US7833707B2 (en) | 2004-12-30 | 2010-11-16 | Boehringer Ingelheim Vetmedica, Inc. | Methods of overexpression and recovery of porcine circovirus type 2 ORF2 |
| US7700285B1 (en) | 2005-12-29 | 2010-04-20 | Boehringer Ingelheim Vetmedica, Inc. | PCV2 immunogenic compositions and methods of producing such compositions |
| UA95602C2 (ru) | 2004-12-30 | 2011-08-25 | Берингер Ингельхейм Ветмедика, Инк. | Иммуногенная композиция цвс2 и способы приготовления такой композиции |
| US8097288B1 (en) * | 2008-04-16 | 2012-01-17 | Pom Wonderful, Llc | Composition and method for providing nutritional immunology for production animals |
| US20070031342A1 (en) * | 2005-06-22 | 2007-02-08 | Nektar Therapeutics | Sustained release microparticles for pulmonary delivery |
| EP1909839A1 (en) * | 2005-08-04 | 2008-04-16 | Wyeth a Corporation of the State of Delaware | Stabilizers for veterinary vaccines |
| CN103536914B (zh) * | 2005-12-29 | 2015-11-11 | 贝林格尔.英格海姆维特梅迪卡有限公司 | 多价pcv2免疫原性组合物和制备此类组合物的方法 |
| KR20140019479A (ko) | 2005-12-29 | 2014-02-14 | 베링거잉겔하임베트메디카인코퍼레이티드 | 돼지에서 임상 증상을 경감시키기 위한 ｐｃｖ2 면역원성 조성물의 용도 |
| EP1911836A1 (en) * | 2006-10-12 | 2008-04-16 | AVIR Green Hills Biotechnology Trading GmbH | Medium supplement for virus production |
| EP2101815A4 (en) | 2006-12-11 | 2010-10-06 | Boehringer Ingelheim Vetmed | EFFICIENT PROCESS FOR THE TREATMENT OF PORCINE CIRCOVIRUS AND LAWSONIA INTRACELLULARIS INFECTIONS |
| CA2670836C (en) * | 2006-12-15 | 2018-09-04 | Boehringer Ingelheim Vetmedica, Inc. | Treatment of pigs with pcv2 antigen |
| EP1941903A1 (en) | 2007-01-03 | 2008-07-09 | Boehringer Ingelheim Vetmedica Gmbh | Prophylaxis and treatment of PRDC |
| EP1958644A1 (en) * | 2007-02-13 | 2008-08-20 | Boehringer Ingelheim Vetmedica Gmbh | Prevention and treatment of sub-clinical pcvd |
| US7829274B2 (en) | 2007-09-04 | 2010-11-09 | Boehringer Ingelheim Vetmedica, Inc. | Reduction of concomitant infections in pigs by the use of PCV2 antigen |
| KR20100113582A (ko) | 2008-01-23 | 2010-10-21 | 베링거잉겔하임베트메디카인코퍼레이티드 | Ｐｃｖ2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법 |
| TWI627281B (zh) | 2009-09-02 | 2018-06-21 | 百靈佳殷格翰家畜藥品公司 | 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物 |
| AR084358A1 (es) | 2010-12-27 | 2013-05-08 | Lilly Co Eli | Composiciones y metodos para identificar y diferenciar componentes virales de vacunas multivalentes de la “fiebre de embarque” (complejo de enfermedad respiratoria bovina (brdc)) |
| AU2011352800B2 (en) * | 2010-12-27 | 2015-09-03 | Elanco Us Inc. | Bovine viral diarrhea virus type 1b vaccine compositions and methods |
| UA114503C2 (uk) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv та mycoplasma hyopneumoniae |
| UA114504C2 (uk) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs |
| US9120859B2 (en) | 2012-04-04 | 2015-09-01 | Zoetis Services Llc | Mycoplasma hyopneumoniae vaccine |
| WO2014182872A1 (en) | 2013-05-08 | 2014-11-13 | Protatek International, Inc. | Vaccine for pcv2 and mycoplasma |
| WO2015048115A1 (en) | 2013-09-25 | 2015-04-02 | Zoetis Llc | Pcv2b divergent vaccine composition and methods of use |
| DK3052516T3 (da) | 2013-10-02 | 2020-03-23 | Boehringer Ingelheim Animal Health Usa Inc | PCV2-ORF2-proteinvariant og viruslignende partikler sammensat deraf |
| JP2021533157A (ja) * | 2018-08-07 | 2021-12-02 | ウィスコンシン アルムニ リサーチ ファンデイション | 組換えの生物学的に封じ込められたフィロウイルスワクチン |
| CN113874496A (zh) | 2019-02-08 | 2021-12-31 | 威斯康星校友研究基金会(Warf) | 人源化细胞系 |
| EP4022046A2 (en) | 2019-08-27 | 2022-07-06 | Wisconsin Alumni Research Foundation (WARF) | Recombinant influenza viruses with stabilized ha for replication in eggs |
| EP4061303A1 (en) * | 2019-11-18 | 2022-09-28 | Elanco Us Inc. | Lyophilized cake in straight-walled vial |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8301996A (nl) * | 1983-06-06 | 1985-01-02 | Duphar Int Res | Werkwijze ter bereiding van geadjuveerde levende vaccins en aldus verkregen geadjuveerde levende vaccins. |
| US4606918A (en) * | 1983-08-22 | 1986-08-19 | Syntex (U.S.A.) Inc. | Polyoxypropylene-polyoxyethylene block polymer based adjuvants |
| US4772466A (en) * | 1983-08-22 | 1988-09-20 | Syntex (U.S.A.) Inc. | Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants |
| ZA953703B (en) * | 1994-05-10 | 1996-01-10 | American Home Prod | Modified live BRSV vaccine |
-
1995
- 1995-05-08 ZA ZA953703A patent/ZA953703B/xx unknown
- 1995-05-08 MY MYPI95001214A patent/MY111829A/en unknown
- 1995-05-08 JP JP52920895A patent/JP3993230B2/ja not_active Expired - Lifetime
- 1995-05-08 AU AU24387/95A patent/AU711350B2/en not_active Expired
- 1995-05-08 EP EP99115633A patent/EP0968722B1/en not_active Expired - Lifetime
- 1995-05-08 EP EP07008378.7A patent/EP1820512B1/en not_active Expired - Lifetime
- 1995-05-08 CA CA2189979A patent/CA2189979C/en not_active Expired - Lifetime
- 1995-05-08 PT PT70083787T patent/PT1820512E/pt unknown
- 1995-05-08 BR BR9507717A patent/BR9507717A/pt not_active IP Right Cessation
- 1995-05-08 DK DK95918442T patent/DK0759780T3/da active
- 1995-05-08 AT AT99115633T patent/ATE365049T1/de active
- 1995-05-08 DE DE69518316T patent/DE69518316T2/de not_active Expired - Lifetime
- 1995-05-08 DK DK99115633T patent/DK0968722T3/da active
- 1995-05-08 EP EP95918442A patent/EP0759780B1/en not_active Expired - Lifetime
- 1995-05-08 KR KR1019960706404A patent/KR100374434B1/ko not_active IP Right Cessation
- 1995-05-08 ES ES99115633T patent/ES2287997T3/es not_active Expired - Lifetime
- 1995-05-08 PT PT95918442T patent/PT759780E/pt unknown
- 1995-05-08 DE DE69535520T patent/DE69535520T2/de not_active Expired - Lifetime
- 1995-05-08 NZ NZ285324A patent/NZ285324A/en not_active IP Right Cessation
- 1995-05-08 PT PT99115633T patent/PT968722E/pt unknown
- 1995-05-08 SI SI9530731T patent/SI0968722T1/sl unknown
- 1995-05-08 ES ES95918442T patent/ES2149361T3/es not_active Expired - Lifetime
- 1995-05-08 WO PCT/US1995/006053 patent/WO1995030437A1/en active IP Right Grant
- 1995-05-08 EP EP07007405A patent/EP1844791A1/en not_active Withdrawn
- 1995-05-08 SI SI9530374T patent/SI0759780T1/xx unknown
- 1995-05-08 CN CNB951939424A patent/CN1268393C/zh not_active Expired - Lifetime
- 1995-05-08 AT AT95918442T patent/ATE195255T1/de active
- 1995-05-08 ES ES07008378T patent/ES2429401T3/es not_active Expired - Lifetime
-
1996
- 1996-04-25 US US08/638,879 patent/US5733555A/en not_active Expired - Lifetime
-
1997
- 1997-12-18 US US08/993,400 patent/US5958423A/en not_active Expired - Lifetime
-
2000
- 2000-06-21 HK HK00103769A patent/HK1024412A1/xx not_active IP Right Cessation
- 2000-09-13 GR GR20000402092T patent/GR3034402T3/el unknown
-
2007
- 2007-03-07 JP JP2007057402A patent/JP2007137905A/ja not_active Withdrawn
-
2011
- 2011-08-26 JP JP2011184908A patent/JP2011246489A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT968722E (pt) | Vacina viva melhorada contra brsv. | |
| EP1742659B1 (en) | Microfluidized oil-in-water emulsions and vaccine compositions | |
| DE602004005460T2 (de) | Adjuvanskombinationen von liposomen und mycobakteriellen lipiden für immunisierungszusammensetzungen und impfstoffe | |
| AU2009282581B2 (en) | Immunological composition | |
| Chu | Modified live BRSV vaccine |